Calendrier des promotions Alterity Therapeutics Limited
Calendrier avancé
Graphique simple
À propos de l'entreprise Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Paramètres de base
IPO date
2002-09-05
ISIN
US02155X1063
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
aud
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 4.09 | 4 |
P/BV | 1.19 | 9 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -82.18 | 0 |
ROE | -104.47 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.0081 | 10 |
Debt/Ratio | 0.0083 | 10 |
Debt/Equity | 0.3932 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 876.58 | 10 |
Rentabilité Ebitda, % | 89.99 | 9 |
Rentabilité EPS, % | 31034.18 | 10 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 4.4 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 4.67 $ | 0 $ | 0 $ | -5.78 % | 0 % | 0 % |
common.calendar.number_days.30d | 4.25 $ | 4.4 $ | 4.4 $ | +3.53 % | 0 % | 0 % |
common.calendar.number_days.90d | 3.14 $ | 3.44 $ | 4.84 $ | +40.35 % | 0 % | 0 % |
common.calendar.number_days.180d | 4.25 $ | 2.54 $ | 4.99 $ | +3.53 % | 0 % | 0 % |
common.calendar.number_days.1y | 1.51 $ | 1.05 $ | 4.99 $ | +191.39 % | 0 % | 0 % |
common.calendar.number_days.3y | 0.6 $ | 0.3201 $ | 35 $ | +633.33 % | 0 % | 0 % |
common.calendar.number_days.5y | 1.46 $ | 0.3201 $ | 35 $ | +201.37 % | 0 % | 0 % |
common.calendar.number_days.10y | 0.3201 $ | 0.3201 $ | 35 $ | +1 374.57 % | 0 % | 0 % |
common.calendar.number_days.ytd | 2.91 $ | 2.54 $ | 4.99 $ | +51.2 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Mr. Geoffrey Paul Kempler B.Sc. | Co-Founder & Non-Executive Chairman | 207.52k | 1955 (70 années) |
Dr. David A. Stamler M.D. | Chief Executive Officer | 613.33k | 1961 (64 année) |
Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of Research & Development Advisory Board | N/A | 1959 (66 années) |
Dr. Robert Cherny | Head of Research | N/A | |
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. | CFO & Company Secretary | N/A | 1959 (66 années) |
Dr. Steven D. Targum M.D. | Chief Medical Advisor |
Informations sur l'entreprise
Adresse: Australia, Melbourne, 350 Collins Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://alteritytherapeutics.com
Site web: https://alteritytherapeutics.com